being crypto- Top People also ask

Market News: Brian Quintenz has become the top contender for the chairmanship of the Commodity Futures Trading Commission (CFTC).Beijing Haidian Joy City will open on December 21st. According to WeChat official account news of "Beijing Haidian" WeChat, Haidian Joy City, the fourth joy city in Beijing, will open on December 21st. At present, many brands have come to an end, and the merchants in the venue have entered the preparations for opening. It is understood that Haidian Joy City is expected to introduce more than 280 brands.In the concept of ice and snow economy, there were many daily limit changes, such as iceberg cold and hot, iceberg cold and hot, Longjian shares and Jingxue energy-saving daily limit, and Dalian Shengya, Changbai Mountain, Yeti shares and Sante ropeway were among the top gainers.

Cao Guo, leader of South Korea's opposition party, the Motherland Reform Party, was sentenced to two years in prison. On the 12th local time, Cao Guo, leader of South Korea's opposition party, was sentenced to two years in prison and lost his parliamentary qualification. (CCTV News)Yunnan Germanium Industry: downstream customers didn't feedback that the company germanium was directly used in quantum chip products. Some investors asked Yunnan Germanium Industry (002428) on the interactive platform: in quantum computing and quantum communication, germanium is widely used in the manufacturing process of quantum chips, which can achieve excellent performance. Excuse me, does the company have germanium products used in quantum chips? Yunnan Germanium Industry replied that at present, the downstream customers of the company have not reported to the company that it is directly used in this product.The retail sector rose and strengthened, and more than 10 stocks such as Yonghui Supermarket rose and strengthened. More than 10 stocks such as Yonghui Supermarket, Maoye Commercial, Zhongbai Group, Nanning Department Store, Youhao Group and Dongbai Group rose and strengthened.

In 2024, the qualification examination and approval of the first batch of new materials insurance compensation was started, and the Ministry of Industry and Information Technology recently issued a notice to organize the qualification examination and approval of the first batch of new materials insurance compensation in 2024. It is clear that the enterprise applying for qualification should be an enterprise that produces and manufactures the products listed in the Catalogue for the Demonstration and Guidance of the First Application of Key New Materials (2024 Edition). It belongs to an independent legal person registered in People's Republic of China (PRC), has strong design and development, manufacturing and industrialization capabilities, has a relatively complete team of professional technicians, and has mastered the core technology and intellectual property rights of this product development. The qualification examination and approval procedures need to go through three steps: enterprise declaration, review by local industrial and information authorities or recommended units such as the central enterprise group, and expert review organized by the Ministry of Industry and Information Technology. After review, the product compensation qualification is determined, and the amount of subsidy funds is approved according to a certain proportion of the product value, and the effective period is no more than 3 years.Trump said that he chose Kari Lake as the director of VOA.Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.